Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
第一作者:
David,Marin
第一单位:
Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom. d.marin@imperial.ac.uk
作者:
医学主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);基因, abl(Genes, abl);人类(Humans);白血病, 髓样, 慢性期(Leukemia, Myeloid, Chronic-Phase);男(雄)性(Male);中年人(Middle Aged);试验预期值(Predictive Value of Tests);蛋白激酶抑制剂(Protein Kinase Inhibitors);蛋白酪氨酸激酶类(Protein-Tyrosine Kinases);嘧啶类(Pyrimidines);缓解诱导(Remission Induction);噻唑类(Thiazoles);时间因素(Time Factors);转录, 遗传(Transcription, Genetic);青年人(Young Adult)
DOI
10.1182/blood-2012-01-407486
PMID
22645182
发布时间
2025-05-29
- 浏览15
Blood
291-4页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



